Memory Studies - Re:Cognition Health

Re:Cognition Health is enrolling volunteers to participate in studies.

Current Studies

Altoida

Detecting an MCI and Amyloid Digital Neuro Signature (DNS) using Altoida’s multimodal digital biomarkers. Ground Truth data collection.

To be eligible for this study, a potential participant must:

Male or female, 50+ years at the time of consent.
At least four years of formal education (from primary school onwards).
Adequate vision to complete the Altoida assessment and neuropsychological tests with or without corrective lenses.
Has Not been in a clinical trial longer than six months of any potential disease-modifying anti-amyloid AD treatment.

Aribio

A placebo-controlled study to evaluate the effects of AR1001 in participants with early AD(more advanced patients with mild to moderate AD).

To be eligible for this study, a potential participant must:

Be between the ages of 55 and 90
Have noticed a change in your memory for the at least 3 years.
Study partner during the study
Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease/ Mild cognitive Impairment.

Gemvax

A placebo-controlled study to evaluate the effect, safety and Efficacy of GV1001 in participants with mild to moderate AD.

To be eligible for this study, a potential participant must:

Be between the ages of 55 and 85
Study partner during study
Mild to moderate Dementia

Prothena

This is a Multiple Ascending Dose Study to Evaluate the safety and tolerability of a drug called PRX012 in Subjects with Alzheimer’s Disease, when compared to a placebo. Joining our clinical trial is a valuable opportunity to contribute to the advancement of medical research while receiving compensation for your participation. Additionally, we may offer reimbursements for clinical trial-related travel expenses and do not require health insurance. Don’t miss out on the chance to make a meaningful impact on the future of healthcare.

To be eligible for this study, a potential participant must:

Be between the ages of 55 and 85
Have a confirmed or suspected diagnosis of mild Alzheimer’s disease or mild cognitive impairment due to Alzheimer’s disease
Have noticed gradual and progressive change in memory function for at least 6 months
Be willing and able to complete brain imaging (MRI and PET scans)

SAGE – Lightwave Study

This is a placebo-controlled study to evaluate the effects of SAGE-718 in participants with Mild Cognitive Impairment or Mild Dementia due to Alzheimer’s Disease. The primary objective of the LIGHTWAVE study is to determine if the cognitive enhancements observed during the two-week LUMINARY dosing period will be sustained over a longer duration. The study will specifically evaluate the effectiveness of the drug using the Digit Symbol Substitution test, a brief cognitive assessment that is highly responsive to changes in cognition and is believed to provide the most accurate reflection of daily cognitive abilities in patients.

To be eligible for this study, a potential participant must:

Be between the ages of 50 and 80
Have noticed a change in your memory
Have a family member or loved one who can be available as a study partner during the study
Be diagnosed with, or have a suspected clinical diagnosis of, Alzheimer’s disease – This is one of our more mild studies, so no diagnosis needed – as long as the patient has noticed significant concerns with their memory

Cognito

Be part of the development of a new device that has the potential to slow the progression of Alzheimer’s disease, from the comfort of home without medications or highly invasive procedures. The objective of this study is to assess the effect of gamma sensory stimulation in individuals with mild/moderate Alzheimer’s Disease on function, cognition and symptoms.

To be eligible for this study, a potential participant must:

Be between the ages of 50 and 85
Have noticed a change in your memory
Have a family member or loved one who can be available as a study partner during the study

Interest Form (Zoho)

Submit your interest to our team of specialists

Attention: Make sure to check that you fit the eligibility requirements which are listed above for each study.
First Name*
Last Name*
Phone Number*
Best time for us to call
Email*
What Best Describes You?*
How old are you?*
Do you have any history of cancer in the last 5 years?*
Do you have any metal work in the body e.g. pacemakers, hip replacements?*
Please select your preferred clinic*
What is the main reason for your inquiry?
Where did you first hear about Re:Cognition?*
CAPTCHA

Our UK and USA clinics are proud to be part of the PPD Select Partnership Programme.

The Re:Cognition Health UK and US site networks are proud to be preferred sites within the PPD Select Partnership Program of Thermo Fisher Scientific’s PPD clinical research business, a global leader in clinical research. We’re excited about the opportunities this relationship brings, and we are looking forward to working with the PPD Strategic Site Collaborations team and evolving our relationship within the PPD Select Program, across our existing ten sites.